Ken Griffin Lian Bio Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.49 - $2.46 $568,806 - $939,102	381,749 Added 302.84%	507,806 $756,000
Q2 2023 Aug 14, 2023	BUY	$1.79 - $2.85 $25,588 - $40,740	14,295 Added 12.79%	126,057 $287,000
Q1 2023 May 15, 2023	SELL	$1.57 - $2.66 $47,776 - $80,946	-30,431 Reduced 21.4%	111,762 $219,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $2.11 $795,692 - $1.47 Million	-697,976 Reduced 83.08%	142,193 $233,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $5,602 - $8,988	2,996 Added 0.36%	840,169 $1.67 Million

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.